Stoke Therapeutics (STOK) director Kahn Clare submits initial Form 3 insider report

Rhea-AI Filing Summary

Stoke Therapeutics director Kahn Clare has filed an initial Form 3 insider ownership report. This filing establishes Clare’s status as a director and baseline reporting position under insider disclosure rules. The filing does not show any insider share purchases, sales, or other transactions at this time.

Key Terms

Form 3, reportingPersons, derivativeSummary

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Kahn Clare""

derivativeSummary financial

""derivativeSummary": []"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kahn Clare

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/03/2026

3. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jonathan Allan, Attorney-in-Fact	04/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Stoke Therapeutics (STOK) Form 3 filed by Kahn Clare represent?

The Form 3 filed for Stoke Therapeutics director Kahn Clare is an initial insider ownership report. It establishes Clare as a reporting insider under SEC rules but shows no share purchases, sales, or derivative transactions in the data provided.

Did Kahn Clare buy or sell any Stoke Therapeutics (STOK) shares in this Form 3?

No, the Form 3 data for Stoke Therapeutics director Kahn Clare shows zero buy and zero sell transactions. The transaction summary lists no purchases, sales, exercises, gifts, or restructurings, indicating only baseline insider status disclosure at this point.

Does the Stoke Therapeutics (STOK) Form 3 for Kahn Clare report any option or derivative positions?

No, the derivative section of the Form 3 data for Kahn Clare is empty. The derivative summary shows no derivative transactions and no remaining option or similar positions reported, reflecting only the insider’s registration as a reporting person.

What does a neutral netBuySellDirection mean in the Stoke Therapeutics (STOK) Form 3?

A neutral netBuySellDirection in this Form 3 means there were no net insider share purchases or sales. For Kahn Clare at Stoke Therapeutics, all transaction counts and share amounts are zero, so there is no directional trading signal in this filing.

Is the Kahn Clare Form 3 for Stoke Therapeutics (STOK) a routine filing?

Yes, this appears to be a routine initial insider ownership filing. Form 3 is typically required when someone becomes a director, officer, or large shareholder, and here it simply records Kahn Clare as a director with no reported transactions yet.